Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD), Chongqing Zhifei - LARVOL DELTA

Parent, Child, and Provider Perspectives on HPV Vaccination in 4-8-Year-Olds: A Mixed Methods Study. (PubMed, J Cancer Educ) - "We conducted semi-structured interviews with a subset of participants in an open-label clinical trial evaluating the 2-dose 9-valent HPV vaccine in children aged 4-8 years old...HPV vaccination in children aged 4-8 was well accepted by parents, feasible for providers, and manageable for children. Trust, education, and strategic integration into routine care may facilitate broader acceptance of early HPV vaccination."

Journal • Oncology • Pediatrics

Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea. (PubMed, Hum Vaccin Immunother) - "Compared to vaccination of girls only with the quadrivalent HPV vaccine, gender-neutral vaccination with the nonavalent HPV vaccine was projected to prevent 1,282,415 cases of cervical intraepithelial neoplasia grade 1 (CIN1), 918,384 cases of CIN2/3, 36,248 cases of cervical cancer, and 9,313 cervical cancer deaths in females over 100 years...The incremental cost-effectiveness ratio (ICER) was ₩38.9 million per quality-adjusted life year (QALY), which is below the accepted cost-effectiveness threshold in South Korea. These findings suggest that gender-neutral vaccination with the nonavalent HPV vaccine would reduce the public health burden of HPV disease in both females and males in South Korea and would be cost-effective under base case assumptions about vaccine price and coverage of boys."

HEOR • Journal • Anal Carcinoma • Cervical Cancer • Dermatology • Genito-urinary Cancer • Gynecology • Head and Neck Cancer • Oncology • Penile Cancer • Solid Tumor

Impact of HPV vaccination after a diagnosis of cervical HSIL - a case-control study. (PubMed, Expert Rev Anticancer Ther) - "Unvaccinated women with genital high-grade lesion(s) were offered vaccination (Gardasil 9®) at the time of treatment.Those with CIN2 or 3 were compared with a historical control group of unvaccinated women...There were no differences in the time until diagnosis.Positive margins (HR [hazard ratio] 8.28; 95% CI 4.08 to 16.77, p  45 years (HR 2.99; 95% IC 1.56 to 5.74, p < 0.001) were associated with increased risk of persistence/recurrence.There was no reduction in HPV detection at 6 months, but vaccinated women were more likely to become HPV negative (HR 0.689; CI 95% 0.54 to 0.89; p = 0.003) and earlier. There was a non-significant trend toward lower risk of recurrence/persistence of CIN2+ after treatment in vaccinated women; vaccination did not impact the short-term HPV detection but increased the likelihood of becoming undetectable."

Journal • Cervical Cancer • Gynecology • Oncology • Solid Tumor

The public health impact of extending the catch-up nonavalent human papillomavirus vaccination program to 2028 in Japan: a model-based study. (PubMed, BMC Public Health) - "Routine vaccination in combination with an extension of the catch-up HPV vaccination strategy for females 17-26 years of age from three to six years may expedite the decrease of morbidity and mortality due to HPV-related diseases in Japan."

Journal • Dermatology • Oncology

HLA-A*11:01-restricted HPV16/18 E6/E7 peptides with stable MHC binding identify prophylactic and therapeutic CD8+ T cell vaccine candidates for Asian populations (ESMO-IO 2025) - "Background Cervical cancer largely caused by high-risk HPV strains accounts for over 170000 deaths annually despite advances in preventive vaccines (e.g Gardasil-9 and Cervarix). 2 in silico hits (1 HPV18 E6 and 1 HPV18 E7) did not bind stably to soluble HLA-A*11:01. Work is ongoing to validate functional immunogenicity of these 15 peptides.Conclusions In silico predictions and in vitro binding assay identified 15 E6/E7 epitopes from HPV16/18, laying the foundation for prophylactic and therapeutic cancer vaccine development in HLA-A*11:01-prevalent populations.Legal entity responsible for the study National Cancer Centre Singapore."

Clinical • Cervical Cancer • Oncology • Solid Tumor • CD8 • IFNG • TNFA

Prevalence and genotype distribution of Human Papillomavirus (HPV) among 14,110 women in Anqing urban area: A population-based cross-sectional survey. (PubMed, PLoS One) - "The highest prevalence rates of HPV infection were observed in women aged <20 years and those aged 50-59 years. Based on these findings, the 9-valent HPV vaccine is strongly recommended as a primary prevention strategy for this population."

Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20-45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial. (PubMed, Front Immunol) - P2 | "The candidate 9vHPV vaccine was well tolerated and immunogenic, supporting further evaluation for efficacy and safety in larger populations. https://clinicaltrials.gov, identifier NCT05694728."

Clinical • Journal • P2 data • Cervical Cancer • Oncology • Solid Tumor

Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. (PubMed, Pediatrics) - No abstract available

Journal

Cost-effectiveness of HPV catch-up vaccination program in women aged 13-24 years in a middle income country. (PubMed, J Gynecol Oncol) - "All catch-up vaccination programs for women aged 13 to 24 years produce additional health benefits and reduce healthcare costs. Vaccination with 9vHPV was considered the most cost-effective option."

HEOR • Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Chlamydia trachomatis Infection and Its Association with Human Papillomavirus Among Adolescent Girls and Young Women of Eastern Cape, South Africa. (PubMed, Epidemiologia (Basel)) - "There was a high burden of C. trachomatis and HPV coinfection. C. trachomatis coinfection influenced HPV genotype prevalence and distribution, including those that are targeted by the current commercial HPV vaccines, suggesting that the high burden of C. trachomatis among AGYW may pose challenges to the ongoing HPV vaccination program. Integrated STI screening and prevention strategies are needed in rural South African settings."

Journal • Infectious Disease • Oncology

The magnitude and durability of neutralizing antibody responses to human papillomavirus vaccine do not depend on DNA sensing pathways. (PubMed, bioRxiv) - "We found no consistent difference in geometric mean nAb titers between mice strains that received 9vHPV at any time point tested or in median HPV16- or HPV18-specific plasma cell frequencies. Thus, we conclude the magnitude and durability of nAb responses to 9vHPV vaccination do not depend on DNA sensing pathways."

Journal • Oncology • MYD88 • STING • TLR9

Effective treatment of a giant condyloma with imiquimod and HPV vaccination. (PubMed, Gynecol Oncol Rep) - "We present a case of successful treatment of an extensive GCA encompassing the entire vulva in a 14-year-old adolescent patient with a history of sexual abuse with imiquimod and three doses of nonavalent HPV vaccination (9vHPV) leading to complete remission of the GCA after 12 weeks of imiquimod application and nearly complete regression of remaining vulvar condylomas after 6 months. Imiquimod in combination with intramuscular 9vHPV vaccination can be an effective treatment for GCA in young patients, without the disfiguring side effects of surgery and could be considered as an alternative treatment option."

Journal • Oncology

Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "The evidence in this network meta-analysis of HPV vaccines is based on extensive searches and analyses. There is evidence from randomised controlled trials that HPV vaccination reduces the risk of pre-cancerous outcomes such as CIN2+ and anogenital warts. No data were available for cervical cancer or other cancer outcomes, and no data on pre-cancer outcomes were available for vaccination under age 15 years. There were no safety concerns noted in the studies."

Clinical • Journal • Retrospective data • Review • Cervical Cancer • Dermatology • Human Papillomavirus Infection • Infectious Disease • Oncology • Penile Cancer • Solid Tumor

Merck-4: The Mother-Daughter Project: a Project to Improve Cervical Cancer Screening and Vaccination Against HPV in Western Kenya (clinicaltrials.gov) - P=N/A | N=2500 | Not yet recruiting | Sponsor: Indiana University

New trial • Cervical Cancer • Gynecology • Oncology • Solid Tumor

Incidence and persistent infection rates of type-specific HPV among HIV-infected males in China: a 5-year retrospective study. (PubMed, Front Public Health) - "Although the 9-valent HPV vaccine (9v-HPV) has been approved for males in China, it has received limited public attention...These findings highlight the increased burden of HPV infection among HIV+ individuals. Timely vaccination will benefit males by preventing HPV infection and consequently reducing the associated disease burden."

Journal • Retrospective data • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology

Seroprevalence of nine human papillomavirus types included in the nonavalent vaccine in unvaccinated women living in Puerto Rico: A population-based study. (PubMed, Int J Infect Dis) - "The high seroprevalence of 9vHPV types found in our study, underscores the potential benefits of following the recommended vaccine schedule to reduce HPV and cervical cancer burden in this population."

Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Alopecia universalis following human papillomavirus vaccine administration: a case report. (PubMed, Clin Exp Vaccine Res) - "Similarly, the development of AA induced by vaccines is a rare occurrence. This report presents a case of a healthy female who developed alopecia universalis after 9vHPV vaccination, aiming to document the event, share treatment, and highlight the need for prompt medical attention."

Journal • Alopecia • Cervical Cancer • Dermatology • Immunology • Oncology • Solid Tumor

Cost-effectiveness of cervical cancer screening and HPV vaccination: a Markov model from the healthcare payer perspective. (PubMed, Front Public Health) - "The model compared the outcomes of bivalent, quadrivalent, and 9-valent HPV vaccines combined with two screening TCT and HPV testing...Within the current resource and policy context, combining HPV testing with the 9-valent vaccine provides the highest economic value. This strategy offers evidence to guide future cervical cancer prevention policies in southern China."

HEOR • Journal • Cervical Cancer • Oncology • Solid Tumor

SYNDEMIC SYNERGY OF TRIPTYCH HPV, HIVAND HSV-2 FOR ONCOGENIC HPV REPLICATION IN FEMALE SEX WORKERS (IPVC 2025) - "HPV-16 and HPV-18 were rarely detected; 63.4% of HR-HPV would be covered by Gardasil-9® vaccine... Congolese FSWs represent a very particular core group of several STIs including HIV, HPV and HSV-2 infections, demonstrating syndemic synergy for the development of HPV-associated cervical lesions. HSV-2 may serve as potential target in the development of new interventions or therapeutic strategies for HPV-associated cervical lesions."

Herpes Simplex • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease

AGE-SPECIFIC HPV GENOTYPE PREVALENCE AMONG WOMEN 25 YEARS AND OLDER IN GHANA: A CROSS-SECTIONAL ANALYSIS (IPVC 2025) - "Among all infections, around 44% were from HR-HPV types covered by the Gardasil 9 vaccine (Merck & Co., Inc., USA)... The HR-HPV prevalence among women 25 years and older in Ghana is high. A nationwide HPV vaccination program and improvement of cervical screening access are warranted to reduce the burden of HPV infections and cervical cancer in the future."

Clinical • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

GLOBE-HPV: SELF-COLLECTED FIRST-VOID URINE-BASED HUMAN PAPILLOMAVIRUS GENOMIC SURVEILLANCE AMONG WOMEN IN BANGLADESH (IPVC 2025) - "Among HPV-positive individuals, 13.3% (n=32) carried types covered by the quadrivalent vaccine (4vHPV), 24.5% (n=59) by the nonavalent vaccine (9vHPV) types, while 75.5% (n=182) carried at least one HPV type and 36.5% (n=88) HR-HPV, which are not targeted by available vaccines. This study provides updated data on HPV types among Bangladeshi women using self-collected FVU samples. The high genetic diversity and prevalence of nonvaccine HPV types highlight the need for ongoing surveillance and strengthened screening efforts, as the national program currently offers only a bivalent HPV vaccine."

Clinical • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Solid Tumor

HUMAN PAPILLOMAVIRUS VACCINE LANDSCAPE (IPVC 2025) - " Since 2006, WHO has approved five HPV vaccines: three bivalent vaccines (Cervarix, Cecolin, and Walrinvax); one quadrivalent vaccine (Gardasil); and one nonavalent vaccine (Gardasil 9). Two domestically licensed vaccines are available in Bangladesh (HPvax) and India (Cervavac)... Global vaccine introduction has made good progress in recent years. Countries that have introduced the vaccine subnationally—such as China, Russia, and India—have large populations and wide geographical areas. The vaccine landscape in China is changing rapidly with more low-cost vaccines becoming available, that will likely further influence global vaccine availability."

Cervical Cancer • Genito-urinary Cancer • Penile Cancer • Solid Tumor

PSYCHOSOCIAL BURDEN OF ANOGENITAL WARTS AMONG ADULTS IN CHINA: A QUALITATIVE STUDY (IPVC 2025) - "Introduction: Anogenital warts (AGW) are a vaccine-preventable condition caused primarily by human papillomavirus (HPV) genotypes 6 and 11, which are targeted by the quadrivalent (4vHPV) and nonavalent (9vHPV) vaccines. AGW imposes a substantial and multidimensional burden on patients' mental health, sexual well-being, and intimate relationships. These findings highlight the need to address the psychological and psychosexual burden of AGW in both clinical care and public health settings. Enhanced health education and expanded HPV vaccination efforts are essential to prevent AGW, alleviate its impact on quality of life, and reduce associated stigma."

Clinical • CNS Disorders • Dermatology • Fatigue • Mood Disorders • Pruritus • Psychiatry

SCALING UP HPV VACCINATION COVERAGE IN INDIA: KARKINOS'S MULTI-MODEL APPROACH TO EQUITY AND ACCESS (IPVC 2025) - "Vaccines used included Gardasil-4, Gardasil-9, and Cervavac. This multi-pronged strategy demonstrates the feasibility and effectiveness of scaling HPV vaccination through context-adaptable models supported by public–private collaboration and digital infrastructure. Building trust, improving affordability, and enhancing community engagement are critical to achieving equitable vaccine coverage. These early outcomes offer a replicable model for national scale-up in India and valuable insights for other low- and middle-income countries aiming to meet the WHO cervical cancer elimination targets."

Cervical Cancer • Solid Tumor

HPV VACCINE EFFECTIVENESS AGAINST CERVICAL CANCER AND PRECANCER IN JAPAN: A TEST-NEGATIVE CASE–CONTROL STUDY (IPVC 2025) - "Introduction: Japan's human papillomavirus (HPV) immunization program for girls aged 12-16 years started in 2010 with the 2-valent vaccine (Cervarix). The 4-valent vaccine (Gardasil) was next introduced to the immunization program in 2011, while the 9-valent vaccine (Gardasil 9) was just recently introduced in 2023... These results indicate the real-world effectiveness of the 2- or 4-valent HPV vaccines after the introduction of the national immunization program in Japan."

Clinical • Cervical Cancer • Gynecology • Oncology • Solid Tumor